Lapatinib and Ceritinib: Interaction Details
- Ceritinib
- Zykadia
- Lapatinib
- Tykerb
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Lapatinib and Ceritinib interaction:
What Happens When You Take Lapatinib With Ceritinib
What can happen when they are taken together (rated Major)
Increased exposure
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
Ceritinib is a strong CYP3A , so taking it together with a CYP3A substrate can raise the substrate's exposure. When ceritinib was given with midazolam, a sensitive CYP3A substrate, the midazolam rose 5.4-fold and its rose 1.8-fold. Sensitive CYP3A substrates should be avoided, and when other CYP3A substrates are given at the same time, a lower dose of the CYP3A substrate should be considered.1
The Lapatinib and Ceritinib Interaction, Explained
Ceritinib can make lapatinib build up in your body. Ceritinib slows down , a liver enzyme that helps clear lapatinib. With less clearing, more lapatinib may stay in your blood, which could raise the chance of side effects such as diarrhea, rash, liver problems, or heart rhythm changes. This is a theoretical concern based on how the drugs work, not on a study of these two together.
Please keep taking both exactly as prescribed. Talk with your pharmacist or doctor, who can adjust and individualize your lapatinib dose and may monitor you more closely.
Mechanism: Ceritinib is a strong . Lapatinib is a /5 (not a ), so is expected to increase lapatinib exposure (, ).
- Magnitude: not studied with lapatinib. Ceritinib increased midazolam AUC 5.4-fold and Cmax 1.8-fold.
- Evidence: theoretical (extrapolated from CYP3A probe data). Onset unspecified.
- Risks: lapatinib toxicity, including diarrhea, , and ( QT liability also possible with ceritinib).
- Management: avoid sensitive CYP3A substrates. If coadministered, consider reducing the lapatinib dose, individualize it, and monitor closely for adverse effects, LFTs, and /electrolytes as clinically indicated.
See the 1 reference behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Lapatinib and Ceritinib Interact
The likely mechanism
of -substrate by ceritinib
How to Manage the Lapatinib and Ceritinib Interaction
Your care team can manage this by tailoring your treatment.
- Keep taking both medicines as prescribed unless your prescriber tells you otherwise.
- Your team may consider a lower lapatinib dose, which is individualized to you, and may monitor you more closely.
- Tell your pharmacist or prescriber about any new symptoms, such as severe diarrhea, rash, yellowing of the skin or eyes, dizziness, or a fast or irregular heartbeat.
- Check with your pharmacist before starting any other medicine, supplement, or grapefruit products.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Lapatinib or Ceritinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there another option that avoids this interaction?
Literature Reports
1 report from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Prescribing information: ZYKADIA oral capsules, ceritinib oral capsules
When a single dose of midazolam (a sensitive ) was given after 3 weeks of ceritinib 750 mg daily under fasted conditions, the midazolam rose 5.4-fold and the rose 1.8-fold, relative to midazolam given alone.1
Lapatinib and Ceritinib: Common Questions
How serious is the Lapatinib and Ceritinib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How is the Lapatinib and Ceritinib interaction managed?
Your care team can manage this by tailoring your treatment. Keep taking both medicines as prescribed unless your prescriber tells you otherwise. Your team may consider a lower lapatinib dose, which is individualized to you, and may monitor you more closely. Tell your pharmacist or prescriber about any new symptoms, such as severe diarrhea, rash, yellowing of the skin or eyes, dizziness, or a fast… Management is individual — always follow your own care team's guidance.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
Ask About the Lapatinib and Ceritinib Interaction
Ask in your own words about taking Lapatinib and Ceritinib together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (1)
- Product Information: ZYKADIA(R) oral capsules, ceritinib oral capsules. Novartis Pharmaceuticals Corporation (per FDA), East Hanover, NJ, 2019. DailyMed
Other Serious Interactions of Lapatinib and Ceritinib
Also serious with Ceritinib
- ColchicineContraindicated
- SimvastatinContraindicated
- Dihydroergotamine InjectionContraindicated
- Dihydroergotamine Nasal SprayContraindicated
Also serious with Lapatinib
These Medications Also Interact With Supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
With Ceritinib
- GrapefruitMajor
- Activated CharcoalMajor
- WineMajor
- American HelleboreMajor
- ArsenicMajor
- BeerMajor
- CesiumMajor
- EphedraMajor
- + 59 more
With Lapatinib
- GrapefruitMajor
- St. John's WortMajor
- Activated CharcoalMajor
- Vitamin EModerate
- GingerModerate
- TurmericModerate
- Black PepperModerate
- GrapeModerate
- + 140 more
Check everything you take with our drug–supplement interaction checker.
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, as soon as they can.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring. This interaction.
- Moderate Can be significant — usually manageable with monitoring.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data.
- ProbableGood supporting evidence, though not definitively proven.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.